Biotechnology

1. Scientific foundations and enabling technologies

Biotechnology applies biological systems to practical problems. Traditional practices such as curd-making, brewing and composting exploit naturally occurring organisms. Modern biotechnology enables more precise intervention through molecular biology, genetic engineering and cell culture. DNA stores hereditary information; genes influence traits through functional products such as proteins. However, most economically important traits, including yield and drought tolerance, involve multiple genes interacting with the environment.

Recombinant DNA technology combines DNA sequences and introduces them into a host using a delivery system, often a plasmid vector. Engineered bacteria or yeast can then manufacture substances such as human insulin. Polymerase chain reaction amplifies selected DNA sequences, while sequencing determines their nucleotide order. Reverse-transcription PCR first converts RNA into DNA and is useful for detecting RNA viruses. These techniques underpin diagnostics, research and biological surveillance.

Genome editing, including CRISPR-Cas systems, makes targeted changes in genetic material. Unlike conventional transgenesis, some editing approaches need not introduce foreign DNA into the final organism. Nevertheless, precision at the target site does not eliminate every unintended effect. Other enabling technologies include tissue culture, monoclonal antibodies, stem-cell systems, bioinformatics and synthetic biology, which designs or redesigns biological components for specified functions.

• Genomics studies genomes; proteomics studies proteins; metabolomics examines small molecules involved in metabolism.
• Marker-assisted selection uses DNA markers to guide breeding without necessarily creating a genetically modified organism.
• A biosimilar is highly similar to an approved reference biological medicine; it is not equivalent to a simple chemical generic.

2. Agriculture, food security and rural livelihoods

Agricultural biotechnology can raise productivity, reduce particular crop losses and improve planting material. Bt crops express insecticidal proteins derived from Bacillus thuringiensis against susceptible target insects. Herbicide-tolerant crops survive specified herbicides, while disease-resistant varieties seek to limit losses from pathogens. These are distinct traits: insect resistance does not automatically confer herbicide tolerance, and neither guarantees higher yields under every farming condition.

Tissue culture permits rapid multiplication of plants, while meristem culture combined with testing can produce disease-free planting material in crops such as banana and potato. Biofertilisers containing organisms such as Rhizobium support nutrient availability; microbial biopesticides assist pest management. Molecular diagnostics enable early detection of plant and livestock diseases. Biofortification can improve nutritional quality through conventional breeding or biotechnology, so not every biofortified crop is genetically engineered.

Farmer benefits depend on seed costs, irrigation, extension services, market access and locally appropriate agronomy. Risks include pest resistance, gene flow, effects on non-target organisms and concentration of seed markets. Refuge planting and integrated pest management help delay resistance. Public-sector breeding, independent field evaluation and affordable access are essential to ensure that smallholders share gains rather than merely bear technology costs.

• Assess each crop–trait–environment combination rather than treating all genetically modified crops as equally beneficial or equally risky.
• Nutrition security also requires dietary diversity, sanitation and public-health measures; improved crops alone cannot eliminate malnutrition.

3. Health, diagnostics and precision medicine

Medical biotechnology supplies vaccines, recombinant proteins, diagnostic kits and targeted therapies. Recombinant insulin reduced dependence on animal-derived sources. Monoclonal antibodies are used against cancers, autoimmune disorders and other conditions. Vaccine platforms include recombinant protein, viral-vector, DNA and mRNA approaches; their manufacturing processes, storage requirements and immune responses differ. Biotechnology also supports rapid pathogen identification and antimicrobial-resistance surveillance.

Gene therapy introduces or modifies genetic material to treat disease, whereas cell therapy administers living cells. CAR-T therapy modifies a patient’s T cells to recognise selected cancer-associated targets. India’s indigenous CAR-T product NexCAR19 received regulatory approval in 2023 for specified B-cell malignancies. This represents domestic innovation, but specialised facilities, patient selection and management of serious adverse effects remain necessary.

Precision medicine uses genetic and other biological information to improve diagnosis or treatment selection. Population genomics can reveal variants relevant to Indian populations, historically underrepresented in many datasets. However, associations must be clinically validated, and genetic findings can affect relatives as well as individuals. Informed consent, secure data handling, genetic counselling and protection against discrimination are therefore integral to responsible deployment.

• Somatic interventions affect the treated individual; heritable germline changes may affect future generations and raise substantially greater ethical concerns.
• Clinical effectiveness does not ensure public-health impact unless products are affordable, accessible and supported by functioning health systems.

4. Industrial, environmental and strategic applications

Industrial biotechnology employs microorganisms, enzymes and cultured cells to manufacture chemicals, medicines, materials and fuels. Enzymes improve processes in detergents, textiles, food processing and paper production. Fermentation can generate organic acids and other platform chemicals. Second-generation biofuels use lignocellulosic feedstocks such as agricultural residues, potentially reducing competition with food crops, although collection costs and pretreatment remain significant challenges.

Environmental applications include biological wastewater treatment, composting, anaerobic digestion and bioremediation. Microorganisms can degrade certain pollutants, while some plants accumulate contaminants through phytoremediation. These techniques are site-specific: performance depends on pollutant chemistry, oxygen, temperature and nutrient availability. Heavy metals cannot be biologically destroyed; they may instead be immobilised, transformed or concentrated for subsequent management.

Strategically, domestic capabilities in vaccines, diagnostic reagents, fermentation equipment and biological manufacturing reduce supply-chain vulnerability. Synthetic biology also has dual-use implications because beneficial capabilities can potentially be misapplied. India therefore needs biological surveillance, skilled personnel, secure laboratories and international cooperation. Environmental claims must be tested through life-cycle assessment, including energy use, water demand, feedstock sourcing and waste disposal.

• Biosafety addresses accidental exposure or release; biosecurity addresses loss, theft, misuse and deliberate harmful use of biological materials.
• Biodegradable and bio-based are different attributes: a material made from biomass is not necessarily readily biodegradable.

5. Indian institutions, regulation and policy

The Department of Biotechnology supports research, infrastructure and human resources. The Biotechnology Industry Research Assistance Council, established in 2012, promotes innovation and industry–academia collaboration, particularly involving start-ups. The BioE3 Policy, approved in 2024, promotes high-performance biomanufacturing. Its focus areas include bio-based chemicals and enzymes, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, and marine and space research.

The Rules, 1989 under the Environment (Protection) Act govern specified activities involving hazardous microorganisms and genetically engineered organisms or cells. Institutional Biosafety Committees supervise relevant institutional work. The Review Committee on Genetic Manipulation operates under DBT, while the Genetic Engineering Appraisal Committee under the environment ministry appraises specified activities, including environmental release. Responsibilities differ by activity and stage; biotechnology is not regulated through a single universal clearance.

In 2022, India exempted genome-edited plants in the SDN-1 and SDN-2 categories that are free from exogenous introduced DNA from Rules 7–11 of the Rules, 1989, subject to applicable guidance. This is not a blanket exemption for all gene-edited products. Drugs and clinical trials fall under the health-sector regulatory framework, including CDSCO, while food safety and other sectoral laws may also apply. The Biological Diversity Act, 2002, as amended, addresses access and benefit-sharing within its statutory scope.

• Regulatory appraisal should distinguish laboratory research, confined trials, environmental release, food use and clinical application.
• The Cartagena Protocol addresses biosafety concerning living modified organisms; the Nagoya Protocol addresses access to genetic resources and benefit-sharing.

6. Challenges and a balanced way forward

India’s challenges include expensive scale-up, limited translational infrastructure, dependence on certain imported inputs, uneven research capacity and uncertainty for investors. Biological manufacturing requires reproducibility, contamination control and validated quality systems. Intellectual-property protection can encourage innovation, but restrictive licensing and high prices may constrain access. Publicly funded research should therefore be accompanied by transparent licensing and suitable access commitments.

Responsible progress requires proportionate, science-based regulation with independent expertise, transparent evidence and post-deployment monitoring. Public participation should address livelihood and ethical concerns without equating every new technique with unacceptable danger. Priorities include shared pilot facilities, regional skills development, stronger clinical and agricultural extension networks, and support for neglected diseases and smallholder crops. Biotechnology should complement conventional breeding, preventive healthcare and ecological management rather than displace them indiscriminately.

• Evaluate innovations through five tests: efficacy, safety, affordability, environmental performance and distributive fairness.
• Connect innovation policy with One Health, recognising the interdependence of human, animal and environmental health.

Previous year questions

Practice questions